MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Ensartinib

CAS No. : 1370651-20-9

MCE 站：Ensartinib

产品活性：Ensartinib (X-396) 是一种有效的双重的 ALK/MET 抑制剂，IC₅₀ 分别 <0.4 nM 和 0.74 nM。

研究领域：Protein Tyrosine Kinase/RTK

作用靶点：Anaplastic lymphoma kinase (ALK)  |  c-Met/HGFR

In Vitro: The ability of Ensartinib (X-396) to inhibit the growth of different cancer cell lines harboring ALK fusions or point mutations is tested. Ensartinib is potent in H3122 lung cancer cells harboring EML4-ALK E13;A20 (IC₅₀: 15nM). Ensartinib is also potent in H2228 lung cancer cells harboring EML4-ALK E6a/b; A20 (IC₅₀: 45 nM). Furthermore, X-376 is potent in SUDHL-1 lymphoma cells harboring NPM-ALK (IC₅₀: 9 nM). X-376 also inhibits SY5Y neuroblastoma cells harboring ALK F1174L, MKN-45 gastric carcinoma cells harboring MET dependent, HepG2 cells ａnd PC-9 lung cancer cell lines harboring EGFR exon 19 del with IC₅₀s of 68 nM, 156 nM, 9.644 μM ａnd 2.989 μM, respectively.

In Vivo: The effects of Ensartinib (X-396) in vivo against H3122 xenografts are examined. A pharmacokinetic study reveals that Ensartinib shows substantial bioavailability ａnd moderate half-lives in vivo. Nude mice harboring H3122 xenografts are treated with Ensartinib at 25mg/kg bid. Ensartinib significantly delays the growth of tumors compared to vehicle alone. In the xenograft experiments, Ensartinib appears well-tolerated in vivo. Mouse weight is unaffected by Ensartinib treatment. Drug-treated mice appear healthy ａnd do not display any signs of compound related toxicity. To further assess potential side effects of Ensartinib, additional systemic toxicity ａnd toxico-kinetic studies are performed in Sprague Dawley (SD) rats. Following 10 days of repeated oral administration of Ensartinib at 20, 40, 80 mg/kg in SD rats, all animals survive to study termination. The no significant toxicity (NST) levels are determined to be 80mg/kg for Ensartinib. At NST levels, Ensartinib achieves an AUC of 66 μM×hr ａnd a C_max of 7.19 μM.

相关产品：Afatinib  |  Crizotinib  |  Cabozantinib  |  Lorlatinib  |  Ceritinib  |  Capmatinib  |  Entrectinib  |  Alectinib  |  Brigatinib  |  Savolitinib  |  Repotrectinib  |  Foretinib  |  NVP-TAE 684  |  Tivantinib  |  PHA-665752  |  Tepotinib  |  BMS 777607  |  Merestinib  |  GSK1838705A  |  Telisotuzumab vedotin  |  CEP-37440  |  Zanzalintinib  |  MS4078  |  AZD-3463  |  Zotizalkib  |  Ensartinib dihydrochloride

热门产品线：重组蛋白  |  药物筛选  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds

品牌介绍:
•   MCE (MedChemExpress) 拥有200 多种全球独家化合物库，我们致力于为全球科研客户提供前沿*全的高品质小分子活性化合物；
•   50,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   产品种类涵盖各种重组蛋白，多肽，常用试剂盒 ，更有 PROTAC、ADC 等特色产品，广泛应用于新药研发、生命科学等科研项目；
•   提供虚拟筛选，离子通道筛选，代谢组学分析检测分析，药物筛选等专业技术服务；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。